Recent 8-K filings for EDAP
Highest-materiality recent filing
FocalTherics Q2 revenue up 39% to $13.2M; net loss widens; $40M offering
- Revenue $13.2M, +39% YoY; U.S. procedure volume +47%; 13 Focal One systems sold vs 9.
- Gross margin 55.6% vs 51.1%; operating loss $8.0M vs $6.6M; net loss $14.4M ($0.38/sh) vs $6.4M.
-
EDAP TMS launches $40M ADS offering at $4.75; net proceeds ~$37.1M
Offering of 8,425,000 ADSs at $4.75 each; expected close Aug 14, 2026.
-
FocalTherics Q2 revenue up 39% to $13.2M; net loss widens; $40M offering
Revenue $13.2M, +39% YoY; U.S. procedure volume +47%; 13 Focal One systems sold vs 9.
-
FocalTherics reports preliminary Q2 2026 HIFU revenue $12.7-13.2M, up 34-39% YoY; ESWL held for sale
Q2 2026 HIFU revenue $12.7M-$13.2M (+34-39% YoY); gross margin 54-56% (+3-5 pts); operating loss ($8.5M)-($7.5M).
-
Presentation at June 1, 2026 Investor Day highlights strategic shift to High Intensity Focused Ultrasound (HIFU) devices.
-
EDAP TMS rebrands as FocalTherics, ticker to FOCL June 1; ESWL/Distribution discontinued ops
Corporate name changes to FocalTherics; ticker symbol switches from EDAP to FOCL effective June 1, 2026.
-
EDAP Q1 2026: record HIFU revenue $11.6M (+78% YoY); net loss $9.1M
HIFU revenue $11.6M, up 78% YoY; total revenue $17.8M vs $14.3M in Q1 2025.
-
EDAP TMS draws €12M second tranche from EIB credit facility; issues warrants at €3.23 strike
Drawdown of €12.0 million under Tranche B of EIB credit facility, expected disbursement late April 2026.
-
EDAP reports record 2025 HIFU revenue up 39% YoY; net loss widens, FY2026 guidance reaffirmed
HIFU revenue €33.1M in FY2025, +39% YoY; Focal One placements up 69% YoY.
-
EDAP reports record Q4 HIFU revenue $12.9-13.3M; issues 2026 guidance $50-54M
Q4 HIFU revenue $12.9-13.3M (record); FY2025 HIFU revenue $36.7-37.2M, up 36-38% YoY.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event other_material